biliary tract cancer

News

Eisai files biliary tract cancer drug tasurgratinib in Japan

Eisai has filed for approval in Japan for tasurgratinib, its small-molecule fibroblast growth factor (FGF) receptor inhibitor, as a treatment for biliary tract cancers wit

News

Imfinzi faces Keytruda competition in biliary tract cancer

MSD’s PD-1 inhibitor Keytruda has been approved by the FDA as a treatment for locally advanced unresectable or metastatic biliary tract cancer (BTC) in combination with ch

News

Redx slumps after it abandons trial of lead cancer drug

Study of porcupine inhibitor RXC004 in combination with Merck's Keytruda will continue.

News

Merck's Keytruda flunks another prostate cancer test

Prostate cancer has proved an elusive target for cancer immunotherapies, and Merck & Co's checkpoint inhibitor Keytruda is the latest to fall short in the disease in a phase 3 trial.

News

Jazz opts in to Zymeworks HER2 drug for $325m upfront

Jazz Pharma has lost little time in deciding to buy into Zymeworks' HER2-directed bispecific antibody zanidatamab, paying $325 million upfront for rights to the drug just weeks after taking

News